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Objective: To retrospectively evaluate the clinical and echocardiographic
criteria of thrombolytic therapy for mechanical heart valve thrombosis.
Methods: Nineteen consecutive patients with 22 instances of prosthetic
heart valve thrombosis (14 mitral, 2 aortic, 3 tricuspid, and 3 pulmonary)
were treated with short-course thrombolytic therapy as first option of
treatment in absence of contraindications. The thrombolytic therapy pro-
tocol consisted of streptokinase (1,500,000 IU in 90 minutes) (n 5 18) in
one (n 5 7) or two (n 5 11) cycles or recombinant tissue-type plasminogen
activator (100 mg in 90 minutes) (n 5 4). Results: Overall success was seen
in 82%, immediate complete success in 59%, and partial success in 23%. Six
patients without total response to thrombolytic therapy underwent surgery,
and pannus was observed in 83%. Six patients showed complications:
allergy, stroke, transient ischemic attack, coronary embolism, minor bleed-
ing, and one death. At diagnosis, 10 patients evidenced atrial thrombus by
transesophageal echocardiography, 3 of whom experienced peripheral
embolism during thrombolysis. Four episodes of rethrombosis were ob-
served (16%). The survivorship was 84% with a mean follow-up of 42.6
months. Conclusions: A short-course of thrombolytic therapy may be
considered first-line therapy for prosthetic heart valve thrombosis. The risk
of peripheral embolism may be evaluated for the presence of atrial
thrombus by transesophageal echocardiography at diagnosis. (J Thorac
Cardiovasc Surg 1998;115:780-4)
Despite the improvements in the design of pros-thetic heart valves and the use of anticoagula-
tion, systemic embolism and valve thrombosis re-
main the most dreaded complications of mechanical
heart valve replacement.1
In 1982 the reported incidence of obstructive pros-
thetic heart valve thrombosis (PHVT) ranged from
0.5% to 6% per patient-year in the aortic and mitral
valve position2 to as high as 20% in the tricuspid
position.3 These rates, however, have been largely
reduced with the new models of prosthetic valves
(4%).4 Although operation has classically been the
standard procedure,4-7 it implies a high mortality (8%
to 60%), especially in New York Heart Association
(NYHA) functional class III and IV, which is the most
frequent at diagnosis. Since Luluaga and colleagues8
first reported successful treatment of tricuspid PHVT
with streptokinase, numerous cases of thrombolytic
therapy (TT) have been reported,9-20 with success
rates of 70% to 89%. The precise role of thrombolysis
for the management of PHVT is not well defined,
however, and its clinical and echocardiographic crite-
ria are still debated. We have used a short course of
TT as our primary mode of therapy for PHVT since
January 1984 and have collected data on our results
retrospectively. The purpose of this report is to analyze
our experience with medical management of PHVT
during a 13-year period.
Methods
From January 1984 to January 1997, 19 patients with
PHVT were treated with TT on 22 occasions in our center
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(three rethrombosis) (Tables I and II). To give an idea of
the incidence of this complication, 2096 mechanical heart
valves were inserted in our institution during the same
period (1698 tilting disk valves and 398 bileaflet valves),
with a total of 1148 patients with mechanical heart valves
following monthly international normalized ratio (INR)
controls. Currently, we recommend that our mechanical
valve patients be maintained on acenocoumarol, adjusted
to maintain the INR at 2 to 3 for aortic and 2.5 to 3.5 for
tricuspid and mitral prosthesis.
PHVT diagnosis was made by a combination of clinical
data (heart failure, absence of prosthetic sounds), fluoro-
scopic examination (abnormal mobility of tilting disks),
and transthoracic Doppler echocardiographic abnormali-
ties (high prosthetic gradient, lack of mobility). In 12 cases
a complementary transesophageal echocardiography
(TEE) was performed to disclose the presence of a large
periprosthetic nonobstructive thrombus. TEE enabled us
to visualize 10 cases of paraprosthetic thrombi, all of them
in the atrial side of mitral or tricuspid prosthesis. Maximal
thrombus size was measured in cases in which TEE was
performed (Table II). Both TEE and transthoracic Dopp-
ler echocardiography were performed in each patient
before and 24 hours after TT in accordance with previ-
ously described standard projections.21-23
Total response to TT was defined as return to the
NYHA functional class before the PHVT on the basis of
clinical and echocardiographic findings (return to normal-
ity of transvalvular gradient). Partial response to TT was
defined as an improvement in the transvalvular gradient
.50% even though status before PHVT was not reached.
Since January 1984, we have used a short course of TT
in all patients with PHVT, provided that the patient had
no contraindications for TT. Streptokinase was given in 18
cases according to the same protocol recommended for
treatment of myocardial infarction (loading dose 250,000
IU in 20 minutes followed by 1,500,000 IU in 90 minutes).
Recombinant tissue-type plasminogen activator (rt-PA),
loading dose 10 mg followed by 90 mg for 90 minutes, was
the fibrinolytic agent used in the remaining four cases.
The choice of rt-PA was due to use of streptokinase in
previous PHVT episodes. In 11 cases a second cycle of
streptokinase was administered when a partial response
was achieved with the first course. Heparin infusion was
introduced after the fibrinolytic treatment when the fi-
brinogen level was greater than 0.5 gm/L and was contin-
ued for 7 to 10 days to obtain a partial thromboplastin
time at least twice the control value. It was then replaced
by acenocoumarol adjusted to obtain optimal INR values.
Changes in the incidence of events were analyzed by
Fisher’s exact probability test.
Results
The clinical characteristics of the patients are
presented in Table I using NYHA criteria. The
study group consisted of 15 women and 4 men, with
Table I. Clinical characteristics of thrombolytic therapy (TT) episodes
Case
No. Age/sex
Years after
operation
Valve
position
Symptoms-TT
(days) NYHA INR ECHO
1 47/M 18 T 30 II O TTE
2 70/M 5 Ao 91 I O TTE
3 47/F 11 M 92 II SO* TEE
4 31/F 6 P 91 III SO TTE
5 47/M 15 M 20 IV SO TTE
6 51/M 3 M 19 I† O TEE
7 63/F 5 M 13 IV SO TEE
8 61/F 2 M 6 III SO* TEE
9 35/F 6 M 2 IV SO* TTE
10 46/F 17 M 14 IV O TEE
11 45/F 0.2 M 4 IV SO* TTE
12 65/F 0.4 M 15 I† SO TEE
13 71/F 7 M 30 IV SO* TEE
14 57/F 0.8 Ao 15 III SO TTE
15 51/F 0.3 T 33 IV SO TEE
16 45/F 10 M 4 IV SO TEE
17 24/F 9 P 276 I SO TTE
18 31/F 8 M 7 III SO* TEE
19 35/F 9 P 7 I O TTE
20 61/F 0.02 M 1 IV SO TTE
21 43/F 10 M 34 III O TEE
22 51/F 0.6 T 1 III O TEE
Ao, Aortic; ECHO, echocardiography performed for diagnosis; INR, anticoagulation level in the 3 months preceding valvular thrombosis; M, mitral; NYHA,
functional class at diagnosis; O, optimal; P, pulmonar; SO, suboptimal; T, tricuspid; TEE, transesophageal echocardiography; TTE, transthoracic
echocardiography.
*Acenocumarol was stopped and switched to heparin within the previous month as preparation for elective surgery or pregnancy.
†Peripheral embolism.
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a mean age at first thrombotic episode of 49 years
(range 24 to 72 years). The presenting symptoms
were heart failure as a result of valve obstruction in
18 cases (9 in NYHA functional class IV, 6 in
NYHA class III, 3 in NYHA class II), non-central
nervous system peripheral embolism in 2 cases, and
absence of prosthetic sounds in the remaining 2
cases (NYHA class I). Consequently, 15 patients
were NYHA class III and IV (68%) and 7 were
NYHA class I and II (32%).
We evaluated the anticoagulation level with
acenocoumarol by INR in the 3 months preceding
the thrombotic episode, and we observed that 68%
of patients had suboptimal levels. In six patients
acenocoumarol was stopped within the previous
month as preparation for elective surgery or preg-
nancy.
The valves involved were 13 tilting disk prostheses
(12 Bjo¨rk-Shiley [Shiley, Inc., Irvine, Calif.], 1 Om-
niscience [Medical Inc., Inver Grove Heights,
Minn.]) and 9 bileaflet (3 St. Jude Medical [St. Jude
Medical, Inc., St. Paul, Minn], 5 Carbomedics [Car-
boMedics, Inc., Austin, Tex.], 1 Duromedics
[Hemex Scientific Inc., Austin, Tex.]).
The mean time elapsed from valve replacement to
the first thrombotic episode was 72 months (range 3
to 216 months). The mean time of duration of
symptoms was 42 days (range 1 to 276 days). In
three patients fibrinolysis was used in the recent
postoperative period (between 20 and 60 days after
surgery).
In our center the incidence of mechanical heart
valves inserted during the period of study was equal
regarding sex, but we found a higher incidence of
PHVT in women. Only two of these women had
PHVT risk factors (both were pregnant).
Fibrinolytic treatment was successful (with one or
two cycles of treatment) in 18 cases (82%). Total
response was achieved in 13 patients (59%) and
partial in 5 patients (23%).
Six patients without total response to TT under-
went surgery for valve replacement without mortal-
ity and with evidence of pannus in five valves (83%).
Three patients presented a total of four episodes
of thrombosis recurrence (18%), at a mean of 12
months after the first thrombotic episode (range 1 to
39 months). A total response was achieved in the
three cases treated again with TT.
No major hemorrhagic events were observed.
Major adverse events were embolic episodes. Sys-
temic embolisms were observed in three cases (19%
of left-sided valves): One case of embolic stroke
with partial recuperation, one episode of transient
ischemic attack, and one case of coronary embolism
with total recuperation. All the embolic episodes
occurred early during the first fibrinolytic infusion.
TT in the first case was discontinued at the begin-
ning of infusion because of the suspicion of brain
hemorrhage, although posterior brain scanning con-
firmed ischemic stroke. At diagnosis, 10 patients had
evidence of atrial thrombus by TEE and 3 of them
experienced peripheral embolism; all cases were in
atrial fibrillation. Embolism was more frequent in
patients in functional class IV (two of the cases).
A pregnant woman with mitral PHVT in pulmo-
nary edema died early because of TT failure. Nec-
ropsy was not performed.
Other minor complications of TT were one case
of minor peripheral bleeding associated with vascu-
lar injury that did not require blood transfusion, and
one case of self-limiting allergy.
The statistical analysis showed no significant dif-
ferences in success rates in relation with valve type
(bileaflet prostheses vs single tilting disk valves) and
valve position.
Follow-up consisted of clinical examination and
echocardiography performed at three monthly inter-
vals to exclude any thrombotic recurrence. Sixteen
Table II. Outcome of thrombolytic therapy (TT)
courses
Case
No.
Paraprosthetic
thrombus size
(mm) TT Result Complication
1 N SK F N
2 N SK TR N
3 7 SK F Allergy
4 N SK TR N
5 N SK TR N
6 6 SK PR Stroke
7 8 SK PR N
8 7 SK TR N
9 N SK F Death
10 6 r-TPA TR N
11 N SK PR N
12 15 SK TR TIA
13 6 SK TR Minor bleeding
14 N SK TR N
15 35 SK TR N
16 N SK TR N
17 N SK F N
18 4 SK TR Coronary embolism
19 N r-TPA TR N
20 N r-TPA PR N
21 N SK PR N
22 32 r-TPA TR N
F, Failure; N, none; Paraprosthetic maximal thrombus size evidenced by
transesophagic echocardiography; PR, partial response; r-TPA, recombi-
nant tissue-type plasminogen activator; SK, streptokinase; TIA, transient
ischemic attack; TR, total response.
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patients were surviving (84%) with a mean time of
follow-up of 42.6 months.
Discussion
Massive thrombosis of a prosthetic heart valve is
always a life-threatening event. The reported oper-
ative mortality ranges between 8% and 60%.3, 5-7 In
1983 Husebye and colleagues6 reported 552 patients
undergoing 617 reoperations for repair or replace-
ment of a prosthetic heart valves and noted an
operative mortality of 5.9% for repeat aortic and
19.6% for repeat mitral valve replacement. They
also showed that surgical risk was related to the
preoperative functional class and the urgency of the
procedure; patients in NYHA functional class III
and IV had a mortality risk ranging from 6% to
41%; urgent procedures had a mortality of 8% to
20%, and that for emergency procedures was 37%
to 55%. In contrast, patients in functional classes I
and II and those undergoing elective procedures
had a mortality of only 0% to 4%, similar to that of
the original operation. Several other investigators
reported mortality rates in agreement with that of
Husebye and colleagues and confirmed the correla-
tion between mortality and advanced NYHA func-
tional class at the time of operation.
Since 1980, numerous series of TT have been
reported for PHVT9-20 (Table III), with success
rates ranging from 70% to 100% and the principal
complication of TT being peripheral embolism.
However, in the largest series reported TT has been
used not as first-line treatment for PHVT but only in
patients in advanced NYHA functional class (III to
IV), assuming that the risk of peripheral embolism
with permanent neurologic damage was lower than
the surgical risk. In these series the second risk of
TT was major hemorrhagic complications, although
in all cases the TT infusion time was at least 12
hours (range 12 to 112 hours). To our knowledge, no
large series of TT as first-line treatment for PHVT
has been reported.
Because most patients with PHVT in our center
were in NYHA class III and IV at diagnosis, we
chose a short course of TT as the first option of
treatment of PHVT to achieve a fast clinical re-
sponse and to reduce the bleeding risk. This course
of TT with infusion of streptokinase in only 90
minutes demonstrated an overall success rate simi-
lar to that in previously reported standard protocols
as evidenced by the presence of pannus in 83% of
the cases without total response to TT. In fact, three
of the four cases with TT failure had symptoms of
long duration (30, 92, and 276 days) (see Tables I
and II), suggesting that the underlying pannus
and/or organized thrombus could have caused TT
resistance. Because TT was more successful in
NYHA class III and IV, this short course of TT is
probably warranted in this group and it is also
probable that TT may allow operation in a more
stable clinical setting, if needed.
The reported incidence of major hemorrhagic
events with TT is 6%.20 We did not find major
hemorrhagic complications that could be related to
the short course of TT, although this excellent result
must be interpreted with caution in such a small
sample size.
The major risk is embolism, probably caused by
fragmentation of the thrombus. Peripheral embo-
lism occurred in three cases (19% of left-sided
prostheses), all of them with a periprosthetic throm-
bus demonstrated at TEE study. Two patients expe-
rienced total recuperation; in the third patient the
permanent neurologic damage was probably related
to the discontinuation of the infusion of streptoki-
nase because of suspected brain hemorrhage. Thus
it seems that after TT, most patients with a throm-
bosed prosthesis in the left side of the heart will not
have permanent neurologic sequelae caused by sys-
temic embolization. These data are also in accor-
dance with observations of patients receiving uroki-
nase for left ventricular thrombus after acute
myocardial infarction.24
Table III. Principal series reported of thrombolytic therapy (TT) for prosthetic heart valve thrombosis
Author Cases Indication TT
Success
rate Embolism Hemorrhage
Witchitz et al9 13 First option 70% N 1
Kurzrok et al12 41 Vble. 78% 15% 5
Martinell et al14 6 NYHA III-IV 67% 1 NR
Roudaut et al15 75 NYHA III-IV 75.6% 24% 1
Silber et al17 10 First option 80% N 4
Vitale et al18 8 NYHA I-II 100% 1 N
Reddy et al19 44 NHYA III-IV 88.6% 1 3
Manteiga et al 22 First option 82% 19% N
N, None; NYHA, functional class; NR, not reported; Vble, compiled cases.
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TEE is a reliable method in the detection of
paravalvular thrombosis, particularly in the nonob-
structive forms and can therefore be helpful in
deciding wether a patient with prosthetic thrombosis
should be treated according to the size of the
thrombus.25
According to our experience and the review of the
literature, it appears that TT may be considered
first-line therapy for prosthetic heart valve occlu-
sion. Patients in NYHA functional classes I and II
achieved best results, with the lowest incidence of
peripheral embolism, and no cases of peripheral
embolism with permanent neurologic damage were
observed. TT may be recommended in patients in
NYHA functional class III and IV on diagnosis of
PHVT because, although the success rate is lower
and the incidence of complications is higher, such
patients form the subgroup with the highest opera-
tive mortality risk. TEE must be considered a reli-
able method for the diagnosis of PHVT because at
the same time it may evaluate the risk of peripheral
embolism.
This is a retrospective study on our experience in 22
PHVT episodes in 19 patients undergoing TT over the
last 13 years. However, it has the advantages of being
the largest single-center series of patients treated with
a short course of TT for PHVT as first-line treatment
with diagnosis by TEE in most cases.
Conclusions
Efficacy of short-course TT was comparable with
that of standard protocols and was the same for
NYHA III and IV as for NYHA I and II. We believe
this TT protocol should be considered first-line
therapy for PHVT. TT may be dangerous in the
presence of left-sided atrial thrombosis, but the risk
of peripheral embolism may be evaluated by TEE.
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